Journal of Clinical Medicine (Nov 2023)

CT Attenuation of Hepatic Pancreatic Cancer Metastases Correlates with Prognostically Detrimental Metastatic Necrosis

  • Stefan Reischl,
  • Sebastian Ziegelmayer,
  • Markus Graf,
  • Joshua Gawlitza,
  • Andreas Philipp Sauter,
  • Manuel Steinhardt,
  • Marie-Christin Weber,
  • Philipp-Alexander Neumann,
  • Marcus Richard Makowski,
  • Fabian Karl Lohöfer,
  • Carolin Mogler,
  • Rickmer Früdd Braren

DOI
https://doi.org/10.3390/jcm12237319
Journal volume & issue
Vol. 12, no. 23
p. 7319

Abstract

Read online

Percutaneous CT-guided biopsy is a frequently performed procedure for the confirmation and molecular workup of hepatic metastases of pancreatic ductal adenocarcinoma (PDAC). Tumor necrosis of primary PDAC has shown a negative prognostic impact in recent studies. This study aims to examine predictability in CT scans and the prognostic impact of necrosis in hepatic metastases of PDAC. In this tertiary-center retrospective cohort study, we included 36 patients with hepatic metastases of PDAC who underwent CT-guided hepatic biopsies. Normalized attenuation of the biopsied metastasis was determined in venous phase contrast-enhanced planning scans obtained prior to biopsy by automatic, threshold-based 3D segmentation and manual, blinded 2D segmentation. A board-certified pathologist specialized in hepatic pathology histologically quantified the tumor necrosis and cellularity of the biopsy cylinders. We found a significant inverse-linear correlation between normalized attenuation and the fraction of necrosis (Pearson’s r = 0.51, p p p < 0.035). In summary, tumor necrosis of PDAC metastases can be estimated from contrast-enhanced CT scans, which could help to improve biopsy sample pattern planning. In addition, liver metastatic necrosis may serve as a prognostic biomarker in PDAC.

Keywords